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IN A RECENT Nature Genetics letter, entitled
‘‘Recurrent AAV2-related insertional mutagenesis
in human hepatocellular carcinomas,’’ Nault and
colleagues1 document that of 193 patients with he-
patocellular carcinoma (HCC), 11 contained an
integrated genome sequence of the wild-type adeno-
associated virus 2 (AAV2), and suggest that AAV2 is
associated with oncogenic insertional mutagenesis
in human HCC.
Because AAV2 has long been known to be a
nonpathogenic human parvovirus2 and, in fact, has
been shown to possess antitumor activity,3–6 it is
critical that the scientific and clinical implications of
these studies be rigorously assessed to justify their
conclusions. We have carefully analyzed the data
presented by Nault and colleagues1 and reached
a conclusion that is at variance with that of the
authors.
The majority of the insertions contained the
AAV2 poly(A) site. In the TNFSF10 (TRAIL [tumor
necrosis factor-related apoptosis-inducing ligand]
gene) cases, AAV2 poly(A) increased TRAIL ex-
pression, which may be desirable because TRAIL,
which selectively kills cancer cells, has been ex-
tensively investigated as a cancer therapy drug.
For CCNA2, insertion in clones 2, 3, and 4 in fact
generated transcripts that encode nonfunctional
CCNA2. For the KMT2B case, the insertion of a
386-bp AAV2 3¢-DNA fragment effectively intro-
duced 5 in-frame stop codons in exon 3 of the gene’s
37 exons, and thus inactivated this allele. Given
that in HCC, this gene is expressed at very high
levels, its inactivation might be desirable as well.
For one of the CCNA2 insertions (CHC2128T), the
authors did not present any RNA data, which
makes it difficult to draw any definitive conclusion
in this case.
The single case of TERT promoter insertion is
also unconvincing. The promoter is taken out of the
sequence context. The TERT promoter is usually
extremely weak in normal cells, and the insertion
is unlikely the cause of TERT activation. Also, the
authors did not show how high the TERT activities
(RNA counts) are in HCC cells without the AAV2
insertion; they may be on the same level regard-
less. The authors use DNA-mediated transfection
assays in two established human hepatoma cell
lines to document a modest 3- to 6-fold increase in
TERT promoter activity to justify their claim that
insertion of AAV2 sequences was responsible for
the genesis of HCC. A more appropriate control
would have been to use primary human hepato-
cytes to establish a causal relationship between
AAV integration and TERT gene overexpression.
The transfection experiments also did not include a
reference reporter gene as an internal control for
transfection errors.
PCR positivity of AAV2 sequences in only 7% of
HCC tumors, while there was 21% in the adjacent
normal liver tissues, further argues against the
authors’ conclusion, and can be further questioned
by their deep sequencing data in only 7 tumors
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versus 20 normal tissues. Overall, our conclusion is
that in the majority of the cases, AAV2 insertion
may have either slowed tumor progression or had
no effect.
It is important to emphasize that up to 90% of
the human population is seropositive for AAV2,7
and this stands in stark contrast to an HCC prev-
alence of fewer than 10 cases of HCC per 100,000 in
the United States, a rate that appears to be in-
creasing coincident with the prevalence of hepati-
tis C virus infection.8 It is difficult to explain this if
AAV infection truly represents a significant risk for
HCC development. Moreover, one of the major lim-
itations of the study by Nault and colleagues1 is the
complete absence of any serological data with ref-
erence to AAV2 antibody positivity among case
subjects and control subjects. The final limitation is
the absence of any information on the possible co-
infection by adenovirus and/or herpesvirus in pa-
tients with HCC, both because these viruses serve as
common natural helper viruses for AAV2 replica-
tion, and because both are known to be associated
with tumorigenesis themselves. Furthermore, in
contrast to established replication-competent on-
cogenic viruses (e.g. HPV, HCV), there is no evi-
dence of insertion of full-length AAV genomes in
AAV-positive HCC. Thus, the study by Nault and
colleagues also fails to establish a causal relation-
ship between replication-competent, fully functional
AAV and HCC.
In general, AAV has been demonstrated to be an
inhibitor rather than an enhancer of carcinogenesis
caused by coinfecting viruses. AAV has been shown
not only to induce selective apoptosis in cells that
lack active p53, but also to inhibit tumor growth in
mice.9 Furthermore, epidemiological data suggest a
protective role for infection by AAV in patients with
cervical carcinoma because only 14% of these pa-
tients were seropositive for AAV,10,11 and AAV has
been shown to inhibit human papillomavirus type
16, a virus well known to be the etiologic agent of
cervical cancer.12
Nault and colleagues1 also mention a few exam-
ples of rodent models in which recombinant AAV
vectors have been shown to induce HCC.13–15 How-
ever, none of the insertions described in their studies
was found in previous studies with mice in which
HCC was reported after AAV gene therapy with
prohibitively high vector doses. Although this may be
a reflection on interspecies differences, it could also
be suggested that the risk of hitting these HCC driver
genes is reduced with rAAV vectors as opposed to
wild-type AAV. Furthermore, data from hundreds of
normal mice treated with rAAV vectors showed no
evidence of malignancy.16,17 Similarly, no evidence of
cancer has been detected in large animals, such as
dogs18 and nonhuman primates,19 administered rel-
atively high doses of rAAV vectors. Perhaps most
importantly, in 117 phase I/II/III clinical trials car-
ried out to date with rAAV vectors,20 no adverse
event, including cancer of any type, has ever been
reported.
The conclusions drawn by Nault and colleagues1
represent an enormous leap from their data. No
comment is made about the possible influence of
Rep, a key viral element not only for integration but
also for its antioncogenic activity, on their findings.
Also, it is important to learn where the integrations
in normal tissues occurred relative to those seen in
tumors. It would also be useful to know which other
changes were seen in the sequences of the genes
(introns) of the patients with HCC but without
predisposing factors. Furthermore, natural infec-
tions with wild-type AAV2 have no demonstrable
connection with administration of current rAAV
vectors. The *5% incidence of HCC associated with
AAV2 integration appears to be a secondary event
after the initiation of tumorigenesis.
In summary, it is difficult to draw any definitive
conclusions from the data presented by Nault and
colleagues,1 given the complexity of the cause-and-
effect relationship. Perhaps, time will tell. On the
contrary, viewed in a more positive light, much like
cervical carcinoma, AAV infection might indeed be
a key factor in preventing HCC in humans.
NOTE ADDED IN PROOF
While our article was being reviewed, Büning
and Manfred similarly challenged the conclusions
by Nault and colleagues in an Editorial entitled:
‘‘Adeno-associated Vector Toxicity—To Be or Not to
Be?’’, which was published in the November 25,
2015 issue of Molecular Therapy (Molecular Therapy,
23: 1673–1675, 2015).
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